Eupraxia Pharmaceuticals is trading 12.33% up at $7.56 in pre-market, based on the provided pre-market price versus the August 21, 2026 close of $6.73; the catalyst remains unconfirmed.
- No new company-specific catalyst dated August 24, 2026 was identified.
- The latest company releases located were August 13 clinical-trial data and August 11 financial results.
- Broader futures are modestly lower, but the move is not clearly explained by market-wide sentiment.